Scarica l'app Stockscreener
114.46
2.49%
2.78
Dopo l'orario di chiusura:
114.46
Rhythm Pharmaceuticals Inc Borsa (RYTM) Ultime notizie
RYTM Maintained by RBC Capital -- Price Target Raised to $141.00 - GuruFocus
Rhythm Pharmaceuticals balances obesity-drug growth prospects and biotech risks - AD HOC NEWS
RBC Capital Adjusts Rhythm Pharmaceuticals Price Target to $141 From $137, Maintains Outperform Rating - marketscreener.com
Rhythm Pharmaceuticals Announces New Data Presentations In Acquired Hypothalamic Obesity At Pediatric Endocrine Society >RYTM - Moomoo
Price to sales forward of Rhythm Pharmaceuticals, Inc. – NASDAQ:RYTM - TradingView
RYTMRhythm Pharmaceuticals Inc Options - Finviz
Rhythm Pharmaceuticals announces public offering of common stock - MSN
Rhythm Pharmaceuticals Inc to Discuss Interim Six-Month Phase 2 Results Evaluating Setmelanotide Call Transcript - GuruFocus
Rhythm Pharmaceuticals (RYTM) CSO exercises RSUs, 2,150 shares withheld for taxes - Stock Titan
Rhythm Pharmaceuticals Stock On Fire: Up 28% With 12-Day Winning Streak - Trefis
Rhythm Pharmaceuticals stock trades up to $111.03 as Rhythm Pharmaceuticals closes offices for July 4th break - Traders Union
Rhythm Pharmaceuticals Stock Surges 28%, With A 12-Day Winning Spree - Trefis
Is Rhythm Pharmaceuticals, Inc. (RYTM) Stock Poised for Growth After Encouraging Setmelanotide Trial Results? - Insider Monkey
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: A Biotech with Promising Upside and Strong Buy Ratings - DirectorsTalk Interviews
(RYTM) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Rhythm Pharmaceuticals highlights obesity pipeline, shares track sector peers - Ad-hoc-news.de
Rhythm Pharmaceuticals Stock On Fire: Up 26% With 10-Day Winning Streak - Trefis
Rhythm Pharmaceuticals 8-K Filing June 2026 – Company Details, Nasdaq Listing, and Executive Information - Minichart
Form 4 Rhythm Pharmaceuticals Inc For: 25 June By Investing.com - Investing.com South Africa
Rhythm Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director JEAN CHRISTOPHE - Moomoo
Rhythm Pharmaceuticals (RYTM) director receives RSUs, options and converts 4,712 RSUs - Stock Titan
[Form 4] RHYTHM PHARMACEUTICALS, INC. Insider Trading Activity - Stock Titan
Rhythm Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director MCGIRR DAVID W J - Moomoo
Director at Rhythm Pharmaceuticals (RYTM) receives new RSUs, options and exercises units - Stock Titan
Rhythm Pharmaceuticals (RYTM) director granted RSUs, stock options and converts RSUs to shares - Stock Titan
Rhythm Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Arbuckle Stuart A - Moomoo
Rhythm Pharmaceuticals (RYTM) director granted RSUs, options and new shares - Stock Titan
Rhythm Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director GOOD JENNIFER L - Moomoo
Rhythm Pharmaceuticals (NASDAQ: RYTM) holders approve directors, pay and Ernst & Young - Stock Titan
Rhythm Pharmaceuticals | 8-K: Current report - Moomoo
Rhythm Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:RYTM) - TradingView
RYTM Forecast — Price Target — Prediction for 2027 - TradingView
Rhythm Pharmaceuticals (RYTM) Is Up 7.9% After Promising Early PWS Data for SetmelanotideWhat's Changed - Sahm
Rhythm Pharmaceuticals(RYTM.US) Director Sells US$3.71 Million in Common Stock - Moomoo
Rhythm Pharmaceuticals (RYTM) director exercises options and sells 37,000 shares - Stock Titan
Rhythm Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director TETRAULT LYNN A. - Moomoo
8-Day Rally Sends Rhythm Pharmaceuticals Stock Up 24% - Trefis
Rhythm Pharmaceuticals (RYTM) Stock Could Be 30.6% Undervalued on Its Growth Narrative - Sahm
Form 144 RHYTHM PHARMACEUTICALS For: 22 June By Investing.com - Investing.com Nigeria
Rhythm Pharmaceuticals stock surges 4.98% as RhythmPharma announces Dr. Shoemaker joins as Senior Medical Director - Traders Union
Form 144 | Rhythm Pharmaceuticals(RYTM.US) Director Proposes to Sell 3.58 Million in Common Stocks - Moomoo
Rhythm Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
[144] RHYTHM PHARMACEUTICALS, INC. SEC Filing - Stock Titan
Can Rhythm Pharmaceuticals (RYTM) ’s New Data Help Patients With a Rare Hunger Disorder? - Insider Monkey
A Quick Look at Today's Ratings for Rhythm Pharmaceuticals(RYTM.US), With a Forecast Between $105 to $155 - Moomoo
CCORF Maintains Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Raises Target Price to $151 - Moomoo
Rhythm Pharmaceuticals Inc (RYTM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Rhythm Pharmaceuticals, Inc. (RYTM) reports Q1 loss, tops revenue estimates - MSN
Rhythm Pharmaceuticals Inc (RYTM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Rhythm Pharmaceuticals Inc (RYTM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Rhythm Pharmaceuticals Inc - TradingKey
Rhythm Pharmaceuticals stock price target reiterated at $130 by TD Cowen By Investing.com - Investing.com South Africa
RYTM Stock Climbs As PWS Data Drive Analyst Upgrades - StocksToTrade
Palatin Technologies Is Pursuing the Next Generation of MC4R. Rhythm Just Reinforced Why That Matters - Benzinga
Rhythm Pharmaceuticals Inc (RYTM) Institutional Confidence - TradingKey
(RYTM) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Rhythm Pharmaceuticals Inc (RYTM) Valuation: PE, PB & Fair Value Analysis - TradingKey
Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Positive Interim Results from Phase 2 Setmelanotide Trial in Prader-Willi SyndromeSlideshow (NASDAQ:RYTM) 2026-06-17 - Seeking Alpha
RYTM News | RHYTHM PHARMACEUTICALS INC (NASDAQ:RYTM) - ChartMill
Rhythm Pharmaceuticals Inc (RYTM) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Rhythm Pharmaceuticals Inc (RYTM) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
1.17%
2.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):